Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer

This study is testing a new drug called HLX43, which is an antibody-drug conjugate (a targeted therapy that delivers chemotherapy directly to cancer cells) that works against PD-L1. The trial is for people with advanced colorectal cancer that has progressed after standard treatments. **You may be eligible if:** - You are between 18 and 75 years old - You have advanced colorectal cancer confirmed by biopsy - Your cancer has progressed after at least one standard treatment, or you could not tolerate standard treatment - You have at least one measurable tumor - Your overall health and organ function are adequate **You may NOT be eligible if:** - You have not tried any prior treatments for colorectal cancer - Your tumors cannot be measured on imaging - You have severe organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.